Dr. Goodman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
100 W Gore St
Ste 406
Orlando, FL 32806Phone+1 407-210-1320Fax+1 321-202-2582
Summary
- Ira Goodman, MD, is a board-certified neurologist specializing in Alzheimer’s disease, Parkinson’s disease, and memory disorders. The current Chief Medical Officer at SiteRx, Dr. Goodman previously ran a successful practice in Orlando, Florida and has been a Principal Investigator in 100+ clinical trials. Dr. Goodman is a 1979 graduate of the Medical College of Pennsylvania. He completed his internship in internal medicine at Orlando Regional Medical Center and his residency in Neurology at Shands Teaching Hospital at the University of Florida.
Education & Training
University of FloridaResidency, Neurology, 1980 - 1983
MCP-Hahnemann College of MedicineClass of 1979
Certifications & Licensure
FL State Medical License 1982 - 2025- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Top MD Consumers Checkbook
Clinical Trials
- Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI) Start of enrollment: 2013 Mar 01
- A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology Start of enrollment: 2013 Jun 01
- A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes Start of enrollment: 2017 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 16 citationsEffect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency: A Randomized Clinical Trial.Peter A. Ljubenkov, Lauren Edwards, Leonardo Iaccarino, Renaud La Joie, Julio C. Rojas
JAMA Network Open. 2021-09-01 - 112 citationsRandomized phase I clinical trial of anti-α-synuclein antibody BIIB054.Miroslaw Brys, Laura Fanning, Serena Hung, Aaron Ellenbogen, Natalia Penner
Movement Disorders. 2019-08-01 - 192 citationsSafety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinica...Joseph Jankovic, Ira J. Goodman, Beth Safirstein, Tonya K. Marmon, Dale Schenk
JAMA Neurology. 2018-10-01
Press Mentions
PUMPING IRONY: A Numbers GameJuly 30th, 2018
New Alzheimer’s Trials Show That Finding Patients for Treatments Is Becoming Insurmountable ObstacleJuly 24th, 2018
REM Sleep Disorder Can Make Sleepers Act Out Violent DreamsJuly 15th, 2017- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
